stockportfolio.pro
BioLife Solutions, Inc. (BLFS)
Healthcare · Medical Instruments & Supplies · NasdaqCM
BioLife Solutions, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $11.02M | $19.74M | $27.37M | $48.09M | $119.16M | $161.76M | $143.27M | $82.25M | $96.21M |
| Gross profit | $4.78M | $6.75M | $13.53M | $18.61M | — | — | — | $41.32M | $50.10M | $62.12M |
| Net income | $-6.88M | $-2.52M | $-25.00M | $-1.66M | $1.98M | $-8.91M | $-139.81M | $-66.43M | $-20.18M | $-4.59M |
| Net margin | — | -22.8% | -126.7% | -6.1% | 4.1% | -7.5% | -86.4% | -46.4% | -24.5% | -4.8% |
Source: BioLife Solutions, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of BioLife Solutions, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BLFS in your portfolio →
About BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
BioLife Solutions, Inc. — frequently asked questions
What is BioLife Solutions, Inc.'s revenue?
BioLife Solutions, Inc. (BLFS) reported revenue of $96.21M for fiscal year 2025, up 17.0% from the prior year, according to its SEC filings.
Is BioLife Solutions, Inc. profitable?
No — BLFS reported a net loss of $-4.59M in fiscal 2025.
What is BLFS's P/E ratio?
BioLife Solutions, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is BioLife Solutions, Inc. growing?
BLFS's revenue grew at roughly 14.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from BioLife Solutions, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.